In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data
As Novo Nordisk hustles up an oral version of its GLP-1 diabetes drug Ozempic for FDA review, the big Eli Lilly competitor has posted another positive late-stage piece of the data puzzle for its rival to Trulicity.
Novo posted a positive profile for its Phase IIIb study combining Ozempic (the injectable semaglutide) with an SGLT-2 drug, comparing it with SGLT-2 plus a placebo. The magic number in this field is an A1C number of 7% or less. Starting with a mean baseline number of 8%, the Ozempic combo cut AIC by 1.5% compared to 0.1% for a placebo — which doesn’t say much for SGLT-2.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.